^
Association details:
| Biomarker: | CTLA4 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2013P - Investigating the clinical relevance of immune checkpoint expression in the peripheral blood of patients with small cell lung cancer (SCLC)
Published date:
10/16/2023
Excerpt:
Moreover, among extensive-stage patients with high expression of CTLA4 and/or TIGIT on PBMCs (n=45 patients), the administration of chemoimmunotherapy was associated with improved survival rates as compared to those receiving chemotherapy only (median OS: 14 vs 7.8 months, p=0.005)...CTLA4 and TIGIT are frequently expressed on PBMCs of SCLC patients and are correlated with significant clinical benefit from the addition of anti-PD-L1 inhibitors to first-line chemotherapy.
Secondary therapy:
Chemotherapy
